Volume 11, Issue 2, Pages (August 2012)

Slides:



Advertisements
Similar presentations
Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.
Advertisements

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Making Proteins in the Powerhouse B. Martin Hällberg, Nils-Göran Larsson Cell Metabolism Volume 20, Issue 2, Pages (August 2014) DOI: /j.cmet
Bone Marrow-Derived Cell Therapy Stimulates Endogenous Cardiomyocyte Progenitors and Promotes Cardiac Repair Francesco S. Loffredo, Matthew L. Steinhauser,
Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.
Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem
Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells David J. Wong, Helen Liu, Todd W. Ridky, David Cassarino, Eran Segal, Howard.
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.
Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.
Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells Keriayn N. Smith, Amar M. Singh, Stephen Dalton Cell Stem Cell Volume 7, Issue.
Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities Koen Schepers, Timothy B. Campbell, Emmanuelle Passegué Cell Stem Cell Volume.
Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Cancer: Inappropriate Expression of Stem Cell Programs?
Kevin Andrew Uy Gonzales, Huck-Hui Ng  Cell Stem Cell 
Leigh Turner, Paul Knoepfler  Cell Stem Cell 
Volume 1, Issue 1, Pages (June 2007)
Human Induced Pluripotent Stem Cells: Now Open to Discovery
Cell Cycle Rules Pluripotency
Why Myc? An Unexpected Ingredient in the Stem Cell Cocktail
A Path to Insulin Independence: “The End of the Beginning”
Volume 9, Issue 2, Pages (August 2011)
Volume 16, Issue 6, Pages (June 2015)
Tamir Rashid, Toshihiro Kobayashi, Hiromitsu Nakauchi  Cell Stem Cell 
Pluripotent Stem Cells from Cloned Human Embryos: Success at Long Last
Gerry P. Crossan, Juan I. Garaycoechea, Ketan J. Patel  Cell Stem Cell 
Roger A. Barker, Malin Parmar, Lorenz Studer, Jun Takahashi 
Blocking HIF1α Activity Eliminates Hematological Cancer Stem Cells
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
Anselme Perrier, Marc Peschanski  Cell Stem Cell 
Transplantable Liver Organoids Made from Only Three Ingredients
Therapeutic Translation of iPSCs for Treating Neurological Disease
Volume 14, Issue 2, Pages (February 2014)
Justin Brumbaugh, Konrad Hochedlinger  Cell Stem Cell 
Stressed-Out HSCs Turn Up p38α and Purine to Proliferate
Small Molecules Take a Big Step by Converting Fibroblasts into Neurons
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Robert Zweigerdt, Ina Gruh, Ulrich Martin  Cell Stem Cell 
Human Induced Pluripotent Stem Cells: Now Open to Discovery
Volume 17, Issue 3, Pages (September 2015)
Stem Cell Aging and Sex: Are We Missing Something?
In This Issue Cell Volume 158, Issue 5, (August 2014)
Why Myc? An Unexpected Ingredient in the Stem Cell Cocktail
Volume 86, Issue 5, Pages (November 2014)
Cutaneous Cancer Stem Cells: β-Catenin Strikes Again
Volume 16, Issue 2, Pages (February 2015)
Recreating Pluripotency?
Blocking HIF1α Activity Eliminates Hematological Cancer Stem Cells
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs
Putting Two Heads Together to Build a Better Brain
Volume 18, Issue 2, Pages (February 2016)
Targeting β-catenin in CML: Leukemia Stem Cells Beware!
Pluripotent Stem Cells and Disease Modeling
Volume 5, Issue 5, Pages (November 2009)
Roger A. Barker, Malin Parmar, Lorenz Studer, Jun Takahashi 
Order from Chaos: Single Cell Reprogramming in Two Phases
Transplantable Liver Organoids Made from Only Three Ingredients
Meddling with METTLs in Normal and Leukemia Stem Cells
Volume 21, Issue 1, Pages (July 2017)
Making HSCs on Demand: Looking Ahead
Direct Conversion Provides Old Neurons from Aged Donor’s Skin
A Fresh Look at iPS Cells
Volume 13, Issue 4, Pages (October 2013)
Chapter 29 - Stem Cells and Generation of New Cells in the
2008–2009 ISSCR Initiatives: Facilitating Communication and Education
Jeremy Sugarman, Andrew Siegel  Cell Stem Cell 
Getting to the Core of Repeat Expansions by Cell Reprogramming
Knocking the Wnt out of the Sails of Leukemia Stem Cell Development
Justin Brumbaugh, Konrad Hochedlinger  Cell Stem Cell 
Presentation transcript:

Volume 11, Issue 2, Pages 147-152 (August 2012) Generating an iPSC Bank for HLA-Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types  Craig J. Taylor, Sarah Peacock, Afzal N. Chaudhry, J. Andrew Bradley, Eleanor M. Bolton  Cell Stem Cell  Volume 11, Issue 2, Pages 147-152 (August 2012) DOI: 10.1016/j.stem.2012.07.014 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Ability of HLA Homozygous Donors to Provide a Zero HLA Mismatch for HLA Heterozygous Recipients (A) Potential for a panel of 405 theoretical homozygous HLA combinations to provide a zero HLA mismatch for all 10,000 potential UK recipients. The cumulative percentage of recipients matched increased steeply with successive theoretical homozygous HLA combinations ranked for utility, until the panel exceeded 100–150 combinations. (B) Ability of an iPSC bank comprising the minimum number of optimal homozygous HLA types (236) known to exist (as volunteer HSC donors on the BMDW registry) to provide a zero HLA mismatch for all 10,000 potential UK recipients. The 236 homozygous HLA types were identified among the 405 theoretical homozygous HLA combinations used in panel (A). Again, the cumulative percentage of recipients matched increased steeply with successive homozygous HLA combinations ranked for utility, but did not exceed 96% due to the absence of certain theoretical homozygous HLA combinations among the >17 million volunteers on the BMDW registry. Cell Stem Cell 2012 11, 147-152DOI: (10.1016/j.stem.2012.07.014) Copyright © 2012 Elsevier Inc. Terms and Conditions